Jefferson Health CEO Cites High Costs of Weight Loss Drugs, Restricts Coverage
Dr. Joseph Cacchione, CEO of the Philadelphia-based nonprofit hospital system Jefferson, revealed that his organization now spends more on prescription drug coverage than on inpatient care, primarily due to the soaring costs of GLP-1 weight loss medications like Wegovy and Zepbound. Prescription drugs accounted for 40% of Jefferson’s insurance spending last year, a significant increase from 14% a decade ago. In 2025, the system's insurance arm reported an $180 million loss, with approximately one-third attributed to GLP-1 coverage. Consequently, Jefferson was forced to lay off over 600 employees as drug costs consumed operating budgets. To mitigate these financial pressures, the insurance plan implemented a new requirement in 2026 mandating that employees participate in diet and lifestyle programs before qualifying for weight loss drug coverage. This restriction has already saved the organization $20 million. Cacchione emphasized that while Jefferson recognizes the medical value of these drugs, the current financial burden is unsustainable, highlighting a broader crisis in healthcare affordability and insurance management amidst the rising popularity of expensive obesity treatments.
Wire timeline
Jefferson Health CEO Cites High Costs of Weight Loss Drugs, Restricts Coverage
Dr. Joseph Cacchione, CEO of the Philadelphia-based nonprofit hospital system Jefferson, revealed that his organization now spends more on prescription drug coverage than on inpatient care, primarily due to the soaring costs of GLP-1 weight loss medications like Wegovy and Zepbound. Prescription drugs accounted for 40% of Jefferson’s insurance spending last year, a significant increase from 14% a decade ago. In 2025, the system's insurance arm reported an $180 million loss, with approximately one-third attributed to GLP-1 coverage. Consequently, Jefferson was forced to lay off over 600 employees as drug costs consumed operating budgets. To mitigate these financial pressures, the insurance plan implemented a new requirement in 2026 mandating that employees participate in diet and lifestyle programs before qualifying for weight loss drug coverage. This restriction has already saved the organization $20 million. Cacchione emphasized that while Jefferson recognizes the medical value of these drugs, the current financial burden is unsustainable, highlighting a broader crisis in healthcare affordability and insurance management amidst the rising popularity of expensive obesity treatments.
nbcnews